Werewolf Therapeutics (NASDAQ:HOWL) Price Target Lowered to $4.00 at JMP Securities

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) had its price target cut by research analysts at JMP Securities from $12.00 to $4.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a "market outperform" rating on the stock. JMP Securities' price target would suggest a potential upside of 196.30% from the company's previous close.

Separately, HC Wainwright reaffirmed a "buy" rating and set a $15.00 price objective on shares of Werewolf Therapeutics in a report on Tuesday, November 19th.

Werewolf Therapeutics Price Performance

Shares of HOWL stock remained flat at $1.35 during trading hours on Tuesday. The stock had a trading volume of 327,018 shares, compared to its average volume of 349,139. The firm has a 50 day moving average of $1.75 and a two-hundred day moving average of $2.10. Werewolf Therapeutics has a 52 week low of $1.31 and a 52 week high of $8.19. The company has a market capitalization of $60.16 million, a P/E ratio of -0.88 and a beta of 0.38. The company has a current ratio of 10.10, a quick ratio of 10.10 and a debt-to-equity ratio of 0.29.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. PFM Health Sciences LP grew its holdings in shares of Werewolf Therapeutics by 4.9% during the 3rd quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company's stock valued at $7,205,000 after purchasing an additional 157,673 shares during the last quarter. Millennium Management LLC grew its stake in shares of Werewolf Therapeutics by 96.4% during the second quarter. Millennium Management LLC now owns 1,110,298 shares of the company's stock valued at $2,709,000 after buying an additional 544,881 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Werewolf Therapeutics by 6.3% in the third quarter. Geode Capital Management LLC now owns 685,989 shares of the company's stock worth $1,454,000 after buying an additional 40,692 shares during the period. State Street Corp increased its holdings in shares of Werewolf Therapeutics by 12.4% in the third quarter. State Street Corp now owns 476,439 shares of the company's stock worth $1,010,000 after buying an additional 52,528 shares during the period. Finally, Acadian Asset Management LLC lifted its stake in shares of Werewolf Therapeutics by 22.8% in the 2nd quarter. Acadian Asset Management LLC now owns 212,296 shares of the company's stock valued at $516,000 after acquiring an additional 39,413 shares during the last quarter. Institutional investors own 64.84% of the company's stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.